The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced ...

Point-of-care testing for common sexually transmitted infections may reduce overuse of antibiotics and improve emergency ...

The GARDP Foundation and Debiopharm have entered a collaboration and license agreement to pursue the development of a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae.

Dutch biotech Intravacc has been given a $14.6 million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world ...

Debio1453 is a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria ...

The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on the rise around the world. The ...

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. today appointed two obstetricians-gynecologists to the ...

Gonorrhoea is a common sexually transmitted infection (STI) that affects millions of people worldwide. Many people who have ...

Sexually transmitted infections (STIs) have been a persistent global challenge, with gonorrhea, caused by the bacterium Neisseria gonorrhoeae, remaining an enduring threat. Despite its clinical and ...